GlassScriptPhysician profile
Neil H Feldman
NPI 1699742486
$2,890.66
in general payments reported to CMS, 2019-2025
16 companies · $531 in 2025
The $531 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $307 · 2021: $193 · 2022: $75.17 · 2023: $578 · 2024: $799 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,051.72 | 2019-2025 | Fasenra, Airsupra, Symbicort |
| Glaxosmithkline, LLC. | $494.86 | 2019-2025 | Nucala |
| Csl Behring | $212.98 | 2023-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $185.08 | 2023-2025 | Takhzyro, Eohilia |
| Biocryst US Sales Co., LLC | $167.21 | 2023-2025 | Orladeyo |
| Genentech USA, INC. | $157.36 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $134.68 | 2019-2025 | |
| Amgen INC. | $104.62 | 2024-2025 | Tezspire |
| Genzyme Corporation | $103.04 | 2021-2024 | |
| Pharming Healthcare, INC. | $86.39 | 2019-2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $49.95 | 2019-2020 | |
| Pfizer INC. | $42.16 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.36 | 2021-2023 | Spiriva Respimat |
| Alk-Abello, INC | $29.65 | 2022 | |
| Mylan Specialty L.P. | $19.42 | 2023 | Yupelri |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $13.18 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.